2021年全球主要慢性肝病负担

IF 6 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Liver International Pub Date : 2025-03-10 DOI:10.1111/liv.70058

Gong Feng, Yusuf Yilmaz, Luca Valenti, Wai-Kay Seto, Calvin Q. Pan, Nahum Méndez-Sánchez, Feng Ye, Silvia Sookoian, Giovanni Targher, Christopher D. Byrne, Wah-Kheong Chan, Sombat Treeprasertsuk, Hon Ho Yu, Seung Up Kim, Jacob George, Wen-Jing Xu, Giada Sebastiani, Ponsiano Ocama, John D. Ryan, Monica Lupșor-Platon, Hasmik Ghazinyan, Saeed Hamid, Nilanka Perera, Khalid Alswat, Vasily Isakov, Qiuwei Pan, Shiv Kumar Sarin, Jörn M. Schattenberg, Mohammadjavad Sotoudeheian, Yu Jun Wong, Ala I. Sharara, Said A. Al-Busafi, Christopher Kenneth Opio, Jin Chai, Yasser Fouad, Yu Shi, Mamun Al-Mahtab, Sujuan Zhang, Carlos Jose Pirola, Vincent Wai-Sun Wong, Ming-Hua Zheng

{"title":"2021年全球主要慢性肝病负担","authors":"Gong Feng, Yusuf Yilmaz, Luca Valenti, Wai-Kay Seto, Calvin Q. Pan, Nahum Méndez-Sánchez, Feng Ye, Silvia Sookoian, Giovanni Targher, Christopher D. Byrne, Wah-Kheong Chan, Sombat Treeprasertsuk, Hon Ho Yu, Seung Up Kim, Jacob George, Wen-Jing Xu, Giada Sebastiani, Ponsiano Ocama, John D. Ryan, Monica Lupșor-Platon, Hasmik Ghazinyan, Saeed Hamid, Nilanka Perera, Khalid Alswat, Vasily Isakov, Qiuwei Pan, Shiv Kumar Sarin, Jörn M. Schattenberg, Mohammadjavad Sotoudeheian, Yu Jun Wong, Ala I. Sharara, Said A. Al-Busafi, Christopher Kenneth Opio, Jin Chai, Yasser Fouad, Yu Shi, Mamun Al-Mahtab, Sujuan Zhang, Carlos Jose Pirola, Vincent Wai-Sun Wong, Ming-Hua Zheng","doi":"10.1111/liv.70058","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>This study utilised the Global Burden of Disease data (2010–2021) to analyse the rates and trends in point prevalence, annual incidence and years lived with disability (YLDs) for major chronic liver diseases, such as hepatitis B, hepatitis C, metabolic dysfunction-associated liver disease, cirrhosis and other chronic liver diseases.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Age-standardised rates per 100,000 population for prevalence, annual incidence and YLDs were compared across regions and countries, as well as the socio-demographic index (SDI). Trends were expressed as percentage changes (PC) and estimates were reported with uncertainty intervals (UI).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Globally, in 2021, the age-standardised rates per 100,000 population for the prevalence of hepatitis B, hepatitis C, MASLD and cirrhosis and other chronic liver diseases were 3583.6 (95%UI 3293.6–3887.7), 1717.8 (1385.5–2075.3), 15018.1 (13756.5–16361.4) and 20302.6 (18845.2–21791.9) respectively. From 2010 to 2021, the PC in age-standardised prevalence rates were−20.4% for hepatitis B, −5.1% for hepatitis C, +11.2% for MASLD and + 2.6% for cirrhosis and other chronic liver diseases. Over the same period, the PC in age-standardized incidence rates were -24.7%, -6.8%, +3.2%, and +3.0%, respectively. Generally, negative associations, but with fluctuations, were found between age-standardised prevalence rates for hepatitis B, hepatitis C, cirrhosis and other chronic liver diseases and the SDI at a global level. However, MASLD prevalence peaked at moderate SDI levels.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The global burden of chronic liver diseases remains substantial. Hepatitis B and C have decreased in prevalence and incidence in the last decade, while MASLD, cirrhosis and other chronic liver diseases have increased, necessitating targeted public health strategies and resource allocation.</p>\n </section>\n </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 4","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Global Burden of Major Chronic Liver Diseases in 2021\",\"authors\":\"Gong Feng, Yusuf Yilmaz, Luca Valenti, Wai-Kay Seto, Calvin Q. Pan, Nahum Méndez-Sánchez, Feng Ye, Silvia Sookoian, Giovanni Targher, Christopher D. Byrne, Wah-Kheong Chan, Sombat Treeprasertsuk, Hon Ho Yu, Seung Up Kim, Jacob George, Wen-Jing Xu, Giada Sebastiani, Ponsiano Ocama, John D. Ryan, Monica Lupșor-Platon, Hasmik Ghazinyan, Saeed Hamid, Nilanka Perera, Khalid Alswat, Vasily Isakov, Qiuwei Pan, Shiv Kumar Sarin, Jörn M. Schattenberg, Mohammadjavad Sotoudeheian, Yu Jun Wong, Ala I. Sharara, Said A. Al-Busafi, Christopher Kenneth Opio, Jin Chai, Yasser Fouad, Yu Shi, Mamun Al-Mahtab, Sujuan Zhang, Carlos Jose Pirola, Vincent Wai-Sun Wong, Ming-Hua Zheng\",\"doi\":\"10.1111/liv.70058\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>This study utilised the Global Burden of Disease data (2010–2021) to analyse the rates and trends in point prevalence, annual incidence and years lived with disability (YLDs) for major chronic liver diseases, such as hepatitis B, hepatitis C, metabolic dysfunction-associated liver disease, cirrhosis and other chronic liver diseases.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Age-standardised rates per 100,000 population for prevalence, annual incidence and YLDs were compared across regions and countries, as well as the socio-demographic index (SDI). Trends were expressed as percentage changes (PC) and estimates were reported with uncertainty intervals (UI).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Globally, in 2021, the age-standardised rates per 100,000 population for the prevalence of hepatitis B, hepatitis C, MASLD and cirrhosis and other chronic liver diseases were 3583.6 (95%UI 3293.6–3887.7), 1717.8 (1385.5–2075.3), 15018.1 (13756.5–16361.4) and 20302.6 (18845.2–21791.9) respectively. From 2010 to 2021, the PC in age-standardised prevalence rates were−20.4% for hepatitis B, −5.1% for hepatitis C, +11.2% for MASLD and + 2.6% for cirrhosis and other chronic liver diseases. Over the same period, the PC in age-standardized incidence rates were -24.7%, -6.8%, +3.2%, and +3.0%, respectively. Generally, negative associations, but with fluctuations, were found between age-standardised prevalence rates for hepatitis B, hepatitis C, cirrhosis and other chronic liver diseases and the SDI at a global level. However, MASLD prevalence peaked at moderate SDI levels.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>The global burden of chronic liver diseases remains substantial. Hepatitis B and C have decreased in prevalence and incidence in the last decade, while MASLD, cirrhosis and other chronic liver diseases have increased, necessitating targeted public health strategies and resource allocation.</p>\\n </section>\\n </div>\",\"PeriodicalId\":18101,\"journal\":{\"name\":\"Liver International\",\"volume\":\"45 4\",\"pages\":\"\"},\"PeriodicalIF\":6.0000,\"publicationDate\":\"2025-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Liver International\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/liv.70058\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/liv.70058","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

本研究利用全球疾病负担数据（2010-2021）来分析主要慢性肝病（如乙型肝炎、丙型肝炎、代谢功能障碍相关肝病、肝硬化和其他慢性肝病）的点患病率、年发病率和残疾生存年数（YLDs）的比率和趋势。方法比较不同地区和国家的年龄标准化患病率、年发病率和死亡率，以及社会人口指数（SDI）。趋势以百分比变化（PC）表示，估计以不确定区间（UI）报告。结果全球范围内，2021年乙型肝炎、丙型肝炎、MASLD和肝硬化等慢性肝病患病率的年龄标准化率为3583.6 （95%UI 3293.6-3887.7）、1717.8 （95%UI 1385.5-2075.3）、15018.1 （95%UI 13756.5-16361.4）和20302.6 （95%UI 18845.2-21791.9）。从2010年到2021年，年龄标准化患病率中，乙肝为- 20.4%，丙肝为- 5.1%，MASLD为+11.2%，肝硬化和其他慢性肝病为+ 2.6%。同期PC的年龄标准化发病率分别为-24.7%、-6.8%、+3.2%和+3.0%。总体而言，在全球一级，乙型肝炎、丙型肝炎、肝硬化和其他慢性肝病的年龄标准化患病率与SDI之间存在负相关关系，但存在波动。然而，MASLD患病率在中度SDI水平时达到峰值。结论：慢性肝病的全球负担仍然很大。在过去十年中，乙型肝炎和丙型肝炎的患病率和发病率有所下降，而MASLD、肝硬化和其他慢性肝病却有所增加，因此需要有针对性的公共卫生战略和资源分配。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Global Burden of Major Chronic Liver Diseases in 2021

Background

This study utilised the Global Burden of Disease data (2010–2021) to analyse the rates and trends in point prevalence, annual incidence and years lived with disability (YLDs) for major chronic liver diseases, such as hepatitis B, hepatitis C, metabolic dysfunction-associated liver disease, cirrhosis and other chronic liver diseases.

Methods

Age-standardised rates per 100,000 population for prevalence, annual incidence and YLDs were compared across regions and countries, as well as the socio-demographic index (SDI). Trends were expressed as percentage changes (PC) and estimates were reported with uncertainty intervals (UI).

Results

Globally, in 2021, the age-standardised rates per 100,000 population for the prevalence of hepatitis B, hepatitis C, MASLD and cirrhosis and other chronic liver diseases were 3583.6 (95%UI 3293.6–3887.7), 1717.8 (1385.5–2075.3), 15018.1 (13756.5–16361.4) and 20302.6 (18845.2–21791.9) respectively. From 2010 to 2021, the PC in age-standardised prevalence rates were−20.4% for hepatitis B, −5.1% for hepatitis C, +11.2% for MASLD and + 2.6% for cirrhosis and other chronic liver diseases. Over the same period, the PC in age-standardized incidence rates were -24.7%, -6.8%, +3.2%, and +3.0%, respectively. Generally, negative associations, but with fluctuations, were found between age-standardised prevalence rates for hepatitis B, hepatitis C, cirrhosis and other chronic liver diseases and the SDI at a global level. However, MASLD prevalence peaked at moderate SDI levels.

Conclusions

The global burden of chronic liver diseases remains substantial. Hepatitis B and C have decreased in prevalence and incidence in the last decade, while MASLD, cirrhosis and other chronic liver diseases have increased, necessitating targeted public health strategies and resource allocation.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Liver International 医学-胃肠肝病学

CiteScore

13.90

自引率

4.50%

发文量

348

审稿时长

2 months

期刊介绍： Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.